Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lirentelimab in H1-Antihistamine Refractory CSU
NCT05528861Phase 2Terminated
- Sponsor
- Allakos Inc.
- Start
- Oct 2022
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in chronic spontaneous urticaria (CSU) comparing Lirentelimab with Placebo (2 arms). Primary endpoint: Absolute Change in Weekly Urticaria Assessment Score (UAS7) From Baseline at 12 weeks. Started Oct 2022; status: terminated.
02
Drugs
lirentelimab
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT05528861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05528861.